肿瘤电场治疗胶质母细胞瘤的进展与展望。

Progress and prospect in tumor treating fields treatment of glioblastoma.

机构信息

Department of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China; Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun 130021, China; NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130021, China.

Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.

出版信息

Biomed Pharmacother. 2021 Sep;141:111810. doi: 10.1016/j.biopha.2021.111810. Epub 2021 Jun 30.

DOI:10.1016/j.biopha.2021.111810

PMID:34214730

Abstract

Glioblastoma (GBM) is a challenging cancer with poor prognosis. The classical standard for treatment is safe resection, followed by concurrent chemoradiotherapy with subsequent adjuvant temozolomide (TMZ). Despite several attempts at different treatments, the 5-year survival rate remains poor. In recent years, with the continuous progress of treatment technology, tumor treating fields (TTFields) were preferable. The device could generate an intermediate frequency alternating electric field and induce apoptosis of some specific types of cancer cells with few toxic and side effects. TTFields induced apoptosis through multiple activations of the pathway. TTFields have been Food and Drug Administration (FDA)-approved for diagnosis and recurrent GBM as additional clinical trial results are revealed. This study reviewed the current status, mechanisms, correlations with immune pathways, the prospects of applying TTFields for GBM, and the adverse events.

摘要

胶质母细胞瘤（GBM）是一种预后不良的具有挑战性的癌症。治疗的经典标准是安全切除，然后进行同步放化疗，随后使用替莫唑胺（TMZ）进行辅助治疗。尽管尝试了几种不同的治疗方法，但 5 年生存率仍然很低。近年来，随着治疗技术的不断进步，肿瘤治疗电场（TTFields）更受欢迎。该设备可以产生中频交变电场，并诱导某些特定类型的癌细胞凋亡，毒性和副作用很小。TTFields 通过多条途径的激活诱导细胞凋亡。随着更多的临床试验结果的揭示，TTFields 已经获得了食品和药物管理局（FDA）的批准，用于诊断和复发性 GBM。本研究综述了 TTFields 在 GBM 中的应用现状、作用机制、与免疫途径的相关性、应用前景及不良反应。